therapeutic interfering particles (TIP) / Gladstone Institute - LARVOL DELTA

Therapeutic interfering particles against HIV (IAS-HIV 2025) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates. (PubMed, Science) - "For HIV, theories have proposed that viral-deletion variants, which conditionally replicate with a basic reproductive ratio [R0] > 1 (termed "therapeutic interfering particles" or "TIPs"), could parasitize wild-type virus to constitute single-administration, escape-resistant antiviral therapies...A single TIP injection also suppressed virus replication in humanized mice and cells from persons living with HIV. These data provide proof of concept for a potential new class of single-administration antiviral therapies."

Journal • Human Immunodeficiency Virus • Infectious Disease

A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters. (PubMed, Proc Natl Acad Sci U S A) - "Recently, intranasally administered RNA-based therapeutic interfering particles (TIPs) were reported to suppress SARS-CoV-2 replication, exhibit a high barrier to resistance, and prevent serious disease in hamsters...Cohoused "contact" animals exposed to infected, TIP-treated animals exhibited significantly lower viral loads, reduced inflammatory cytokines, no severe lung pathology, and shortened shedding duration compared to animals cohoused with untreated infected animals. TIPs may represent an effective countermeasure to limit SARS-CoV-2 transmission."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Discovery and Engineering of a Therapeutic Interfering Particle (TIP) for HIV-1: a single-administration antiviral (IMMUNOLOGY 2022) - "Strikingly, a single injection of an SIV-based TIP lentiviral vector delivered to infant rhesus macaques that were subsequently infected intravenously with SHIV lowered set point viremia by 2-3 log10 for over 5 months. These data provide proof-of-concept for a class of biologic with the potential to circumvent significant barriers to HIV-1 control."

Human Immunodeficiency Virus • Infectious Disease

Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. (PubMed, Cell) - "However, theories predict that robust, therapeutic DIPs (i.e., therapeutic interfering particles, TIPs) must conditionally spread between cells with R >1...In hamsters, both prophylactic and therapeutic intranasal administration of lipid-nanoparticle TIPs durably suppressed SARS-CoV-2 by 100-fold in the lungs, reduced pro-inflammatory cytokine expression, and prevented severe pulmonary edema. These data provide proof of concept for a class of single-administration antivirals that may circumvent current requirements to continually update medical countermeasures against new variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases